| 5594 |
Centers for Disease Control and Prevention |
Html |
en |
Sulfuryl fluoride - NIOSH Pocket Guide to Chemical Hazards |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 5922 |
Centers for Disease Control and Prevention |
Html |
en |
o-Nitrotoluene - NIOSH Pocket Guide to Chemical Hazards |
null |
| MPEG | 0.378858 |
| search | 0.263099 |
| PDF | 0.261307 |
| PPT | 0.446092 |
|
| DOC | 0.368812 |
| information | 0.262482 |
| different file formats | 0.938484 |
| page | 0.276773 |
|
CLICK HERE |
| 6485 |
Centers for Disease Control and Prevention |
Html |
en |
Implementing the MOVE! weight-management program in the Veterans Health Administration, 2007-2010: a qualitative study |
One-third of US veterans receiving care at Veterans Health Administration (VHA) medical facilities are obese and, therefore, at higher risk for developing multiple chronic diseases. |
| resource availability | 0.691782 |
| program | 0.888295 |
| senior management support | 0.661835 |
| physician champion | 0.740844 |
| new program participants | 0.634858 |
| organizational factors | 0.677993 |
| service line chiefs | 0.664568 |
| facility chief nurse | 0.65394 |
| innovation champion | 0.714888 |
| evidence-based weight-management program | 0.72913 |
| interview participants | 0.884816 |
| medical center program | 0.64103 |
| holistic case study | 0.638986 |
| case study design | 0.642816 |
| Qualitative data analysis | 0.642498 |
| senior managers | 0.679688 |
| primary care physicians | 0.829389 |
| case study | 0.707047 |
| health care facilities | 0.679466 |
| different VHA facilities | 0.641143 |
| primary care service-line | 0.64296 |
| program implementation | 0.72786 |
| obesity screening rates | 0.810744 |
| innovation champions | 0.64698 |
| management support | 0.7172 |
|
| innovation implementation fosters | 0.672981 |
| service-line chief support | 0.639389 |
| case study research | 0.665436 |
| multidisciplinary weight-management program | 0.681552 |
| VHA medical facility | 0.663766 |
| health care | 0.698156 |
| VHA primary care | 0.650866 |
| innovation | 0.8316 |
| organizational readiness | 0.662825 |
| program activity | 0.654868 |
| weight-management program | 0.768434 |
| multidisciplinary team | 0.689375 |
| implementation | 0.941356 |
| VHA policy | 0.698987 |
| physical activity | 0.644247 |
| national program officials | 0.67334 |
| innovation implementation | 0.698704 |
| treatment options | 0.680348 |
| VHA facilities | 0.729625 |
| primary care | 0.995444 |
| Veterans Health Administration | 0.696845 |
| VHA medical facilities | 0.838252 |
| facilities | 0.934053 |
| facility | 0.886055 |
|
CLICK HERE |
| 6597 |
Centers for Disease Control and Prevention |
Html |
en |
Surveillance for Chronic Hepatitis B Virus Infection - New York City, June 2008-November 2009 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| chronic HBV patients | 0.639618 |
| newly reported patients | 0.329966 |
| chronic HBV population | 0.44802 |
| hepatitis B virus | 0.300361 |
| acute HBV | 0.432159 |
| enhanced HBV surveillance | 0.455102 |
| New York City | 0.400913 |
| high HBV prevalence | 0.442568 |
| HBV testing | 0.58734 |
| HBV infection surveillance | 0.472579 |
| vaccination status | 0.42683 |
| newly-reported HBV patients | 0.478499 |
| commonly reported reason | 0.357176 |
| NYC clinicians | 0.313465 |
| clinicians | 0.586804 |
| HBV transmission | 0.408376 |
| birth country | 0.466348 |
| hepatitis A vaccination | 0.321206 |
| HBV | 0.979922 |
| enhanced surveillance | 0.299507 |
| random sample | 0.305075 |
| HBV surveillance | 0.58312 |
| HBV surveillance database | 0.546195 |
| risk factors | 0.344207 |
| newly reported cases | 0.314309 |
|
| limited hepatitis surveillance | 0.301041 |
| HBV test results | 0.473828 |
| DOHMH staff members | 0.328423 |
| liver function test | 0.320672 |
| chronic HBV infection | 0.818163 |
| HBV infection status | 0.495096 |
| confirmed chronic HBV | 0.467339 |
| relevant clinicians | 0.305888 |
| function test results | 0.321826 |
| HBV prevalence | 0.506889 |
| HBV core antigen.* | 0.47493 |
| randomly selected HBV | 0.494646 |
| HBV DNA | 0.45964 |
| health departments | 0.306197 |
| HBV patients | 0.652631 |
| chronic HBV | 0.820352 |
| staff members | 0.329461 |
| elevated liver function | 0.320119 |
| positive HBV test | 0.63336 |
| HBV screening | 0.421713 |
| chronic hepatitis | 0.324598 |
| HBV infection | 0.904882 |
| chronic HBV surveillance | 0.527085 |
| close contacts | 0.306384 |
|
CLICK HERE |
| 7508 |
Centers for Disease Control and Prevention |
Html |
en |
Disaster Training and Response - Preparedness and Response for Public Health Disasters |
The Health Studies Branch (HSB) provides expertise and leadership in epidemiology to local, state, federal and international partners to help them prepare for and respond to natural and man-made public health disasters. To do this, HSB conducts surveillance, rapid needs assessments, epidemiology studies, and provides training in disaster epidemiology to public health professionals. |
| HSB guidance document | 0.617214 |
| public health disaster | 0.574451 |
| public health practitioners | 0.351671 |
| disaster response capacity | 0.492973 |
| disaster epidemiology skills | 0.531188 |
| disaster epidemiology | 0.951016 |
| Health Studies Branch | 0.729349 |
| Engaging At-Risk Groups | 0.31749 |
| man-made disasters | 0.481058 |
| Surveillance desk | 0.258744 |
| HSB consultation | 0.539092 |
| disaster preparedness | 0.36351 |
| Environmental Health | 0.283374 |
| disaster epidemiology training | 0.899604 |
| public health partners | 0.522383 |
| disaster-related rapid needs | 0.304299 |
| public health emergencies | 0.544675 |
| health emergency response | 0.402265 |
| Emergency Operations Center | 0.329213 |
| socially vulnerable populations | 0.300083 |
| health surveillance data | 0.412546 |
| international public health | 0.522448 |
| Epidemiology Training Request | 0.374986 |
| disaster preparation | 0.400359 |
| final comprehensive capstone | 0.29058 |
|
| shelter surveillance | 0.264538 |
| morbidity surveillance | 0.279151 |
| major public health | 0.414376 |
| response training course | 0.348937 |
| local health department | 0.354356 |
| disaster response activities | 0.664015 |
| at-risk groups | 0.416761 |
| hsb disaster response | 0.986641 |
| technical assistance | 0.442597 |
| health services | 0.287236 |
| Online Training Course | 0.31504 |
| emergency response capacity | 0.353242 |
| public health | 0.976279 |
| emergency managers | 0.295214 |
| response procedures | 0.258637 |
| American Red Cross | 0.313624 |
| mortality surveillance | 0.356238 |
| rapid needs assessments | 0.458794 |
| contact Health Studies | 0.3634 |
| contact Amy Schnall | 0.299811 |
| disaster experts | 0.393799 |
| Download Participant Workbook | 0.289976 |
| community needs assessment | 0.294482 |
| Field Epidemiology | 0.266726 |
|
CLICK HERE |
| 8835 |
Centers for Disease Control and Prevention |
Html |
en |
Notifiable Diseases and Mortality Tables - May 31, 2013 |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| H. influenzae | 0.38509 |
| National Center | 0.301929 |
| cases | 0.377862 |
| CDC | 0.294349 |
| novel influenza | 0.641872 |
| Total case counts | 0.45721 |
| pandemic influenza | 0.948926 |
| ** Data | 0.348031 |
| Cumulative total E. | 0.475364 |
|
| measles case | 0.344225 |
| Influenza Division | 0.440253 |
| 2009 pandemic | 0.76539 |
| probable cases | 0.327103 |
| Respiratory Diseases | 0.308257 |
| rubella cases | 0.309464 |
| human infection | 0.329695 |
| influenza A virus | 0.474686 |
|
CLICK HERE |
| 8903 |
Centers for Disease Control and Prevention |
Html |
en |
Malaria - About Malaria - FAQs |
Frequently asked questions about malaria, disease, transmission, symptoms, diagnosis, treatment, complications with pregnancy, prevention, eradication and endemic areas. |
| red blood cells | 0.390702 |
| malaria medicines | 0.494516 |
| professional medical care | 0.355949 |
| contracting malaria | 0.493517 |
| Page | 0.399529 |
| effective antimalarial drugs | 0.366575 |
| effective malaria vaccine | 0.505889 |
| antimalarial drugs chloroquine | 0.358928 |
| Plasmodium falciparum | 0.357673 |
| malaria parasite | 0.553795 |
| antimalarial drugs | 0.490421 |
| P. falciparum | 0.339014 |
| good antimalarial drugs | 0.359432 |
| malaria infection | 0.504473 |
| malaria drugs | 0.56295 |
| flu-like illness | 0.354 |
| area | 0.346392 |
| Malaria self-treatment | 0.476341 |
| countries | 0.346836 |
| microscopic malaria parasites | 0.537481 |
| Africa south | 0.345101 |
| effective malaria treatment | 0.491815 |
| malaria attacks | 0.473723 |
| P. ovale | 0.378287 |
| malaria parasites | 0.642919 |
|
| malaria treatment medicines | 0.488916 |
| antimalarial drug Malarone | 0.348517 |
| malaria causes | 0.516926 |
| United States | 0.508077 |
| malaria exists | 0.477573 |
| malaria | 0.906829 |
| malaria preventive drugs | 0.502806 |
| previous blood meal | 0.338326 |
| P. vivax | 0.369454 |
| No. Malaria | 0.503669 |
| solid malaria control | 0.49259 |
| transfusion-transmitted malaria | 0.479843 |
| effective malaria | 0.514094 |
| blood transfusion | 0.337891 |
| principal malaria mosquito | 0.496796 |
| malaria treatment medication | 0.489894 |
| disease | 0.365987 |
| breast milk | 0.35484 |
| malaria immunity | 0.493244 |
| people | 0.366376 |
| infected person | 0.346204 |
| health-care provider | 0.44702 |
| malaria transmission | 0.769011 |
| antimalarial drug | 0.397215 |
|
CLICK HERE |
| 10925 |
Centers for Disease Control and Prevention |
Html |
en |
Effectiveness of Interventions to Increase Cancer Screening |
The Community Preventive Services Task Force published updated findings on the effectiveness of nine interventions aimed at increasing screening for breast, cervical, and colorectal cancers. |
| screening | 0.825295 |
| evidence | 0.702476 |
| Vernon SW | 0.484647 |
| Health professionals | 0.491296 |
| client incentives | 0.498477 |
| lay people | 0.48984 |
| one-on-one education | 0.643519 |
| medical office | 0.490363 |
| sufficient evidence | 0.586064 |
| structural barriers | 0.519999 |
| different settings | 0.490959 |
| colorectal cancer screening | 0.79436 |
| insufficient evidence | 0.585195 |
| health advisor | 0.489435 |
| Preventive Services Task | 0.750152 |
| Wilson KM | 0.482698 |
| Melvin CL | 0.488376 |
| colorectal cancer | 0.856728 |
| client reminders | 0.787952 |
| cervical cancer screening | 0.749418 |
| mass media | 0.495716 |
| cervical cancers | 0.520315 |
| telephone messages | 0.485305 |
| American Journal | 0.484797 |
| group education | 0.6356 |
|
| Rimer BK | 0.495965 |
| colorectal cancers | 0.650045 |
| Preventive Medicine. | 0.505873 |
| Mercer SL | 0.48551 |
| group members | 0.494349 |
| provider incentives | 0.494362 |
| Sabatino SA | 0.489436 |
| blood testing | 0.502669 |
| public health care | 0.589479 |
| strong evidence | 0.617647 |
| teaching aids | 0.493319 |
| suffıcient evidence | 0.631728 |
| breast cancer | 0.51161 |
| Services Task Force | 0.733804 |
| community setting | 0.493461 |
| one-on-one education increases | 0.611101 |
| provider assessment | 0.493201 |
| recipient’s characteristics | 0.489913 |
| out-of-pocket costs | 0.497968 |
| Community Preventive Services | 0.987048 |
| telephone reminders | 0.521448 |
| Community Guide | 0.506322 |
| systematic reviews | 0.483978 |
| FOBT screening | 0.71029 |
|
CLICK HERE |
| 12476 |
Centers for Disease Control and Prevention |
Video |
en |
June 2013 ACIP Meeting -- Influenza |
Introduction by Dr. W Keitel. Epidemiology/surveillance update by Dr. L Finelli. H7N9 update by Dr. D Jernigan. Preliminary data on 2012-2013 vaccine effectiveness by Dr. M Thompson. Vaccine safety update by Dr. T Shimabukuro. FluLaval Quadrivalent: GSK's inactivated quadrivalent seasonal influenza vaccine manufactured in Quebec by Dr. V Jain. 2013-2013 recommendations by Dr. L Grohskopf.
Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html
This video can also be viewed at: http://streaming.cdc.gov/vod.php?id=346a288deb884b40d8e72dd413801af020130730150920062. |
|
|
CLICK HERE |
| 15963 |
Centers for Disease Control and Prevention |
Html |
en |
Zika Virus Infection and Microcephaly |
Information on Zika virus. Provided by the U.S. Centers for Disease Control and Prevention. |
| Zika Virus Infection | 0.969937 |
|
|
CLICK HERE |